Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Nov;136(5):902-903.
doi: 10.1097/AOG.0000000000004126.

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Erin M Cleary  1 , R Kate Byron, Katherine A Hinely, Allison W Talley, Maged M Costantine, Kara M Rood
Affiliations
Clinical Trial

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

Erin M Cleary et al. Obstet Gynecol. 2020 Nov.
No abstract available

PubMed Disclaimer

Comment in

  • Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women.
    Bernstein SN, Peckham AM, Schiff DM, Gray JR. Bernstein SN, et al. Obstet Gynecol. 2021 Feb 1;137(2):377-378. doi: 10.1097/AOG.0000000000004270. Obstet Gynecol. 2021. PMID: 33481516 No abstract available.
  • In Reply.
    Cleary EM, Kate Byron R, Hinely KA, Talley AW, Costantine MM, Rood KM. Cleary EM, et al. Obstet Gynecol. 2021 Feb 1;137(2):378. doi: 10.1097/AOG.0000000000004269. Obstet Gynecol. 2021. PMID: 33481517 No abstract available.

References

    1. Cleary EM, Byron RK, Hinely KA, Talley AW, Costantine MM, Rood KM. Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. Obstet Gynecol 2020;136:902–3. doi: 10.1097/AOG.0000000000004126 - DOI - PMC - PubMed
    1. Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019;13:93–103. doi: 10.1097/ADM.0000000000000457 - DOI - PMC - PubMed
    1. Winhusen T, Lofwall M, Jones HE, et al. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemp Clin Trials 2020;93:106014. doi:10.1016/j.cct.2020.106014 - DOI - PMC - PubMed

Publication types